ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$4.78 USD
-0.19 (-3.82%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $4.77 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for ADC Therapeutics SA falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 70 | 210 | 34 | 0 | 2 |
Cost Of Goods | 3 | 5 | 1 | 0 | 0 |
Gross Profit | 67 | 205 | 33 | 0 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 233 | 329 | 294 | 219 | 122 |
Income After Depreciation & Amortization | -166 | -124 | -262 | -219 | -119 |
Non-Operating Income | 17 | 6 | 29 | -22 | 4 |
Interest Expense | 46 | 37 | 18 | 5 | 0 |
Pretax Income | -195 | -155 | -252 | -246 | -116 |
Income Taxes | 39 | 1 | -21 | 0 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | -6 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -240 | -156 | -230 | -246 | -116 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -240 | -156 | -230 | -246 | -116 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -163 | -121 | -259 | -217 | -118 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 3 | 2 | 2 |
Income After Depreciation & Amortization | -166 | -124 | -262 | -219 | -119 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 81.71 | 78.29 | 76.75 | 65.33 | 49.28 |
Diluted EPS Before Non-Recurring Items | -2.94 | -1.99 | -3.00 | -3.77 | -2.36 |
Diluted Net EPS (GAAP) | -2.94 | -1.99 | -3.00 | -3.77 | -2.36 |
Fiscal Year end for ADC Therapeutics SA falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 16.79 | 14.49 | 19.28 | 18.99 |
Cost Of Goods | NA | 0.25 | 0.37 | 1.32 | 0.59 |
Gross Profit | NA | 16.54 | 14.13 | 17.96 | 18.40 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 53.75 | 51.53 | 57.75 | 69.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -37.21 | -37.40 | -39.79 | -51.57 |
Non-Operating Income | NA | 10.22 | 2.45 | 1.92 | 2.30 |
Interest Expense | NA | 7.11 | 12.94 | 15.86 | 10.42 |
Pretax Income | NA | -34.11 | -47.89 | -53.73 | -59.69 |
Income Taxes | NA | 46.06 | -0.09 | -6.61 | -0.26 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | -5.53 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -85.70 | -47.81 | -47.12 | -59.43 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -85.70 | -47.81 | -47.12 | -59.43 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 82.29 | 82.43 | 81.47 | 80.31 |
Diluted EPS Before Non-Recurring Items | NA | -1.03 | -0.58 | -0.58 | -0.74 |
Diluted Net EPS (GAAP) | NA | -1.04 | -0.58 | -0.58 | -0.74 |